1,721,105 research outputs found
Bone grafts and adjuvant chemotherapy for the treatment of canine distal radial osteosarcoma: 34 cases
No full textreview dei risultati clinici dei nostri cas
Canine epithelial thymic tumors: Outcome in 28 dogs treated by surgery
No full textThymoma is a tumor rarely reported in dogs and should be differentiated from mediastinal lymphoma. Clinical signs may have a late onset, and thymoma is often diagnosed when symptoms related to the space‐occupying effect or paraneoplastic syndromes occur. CT and fine-needle aspirates or core biopsies are helpful in differential diagnosis, but flow cytometry may improve the pre‐operative diagnostic ability. Concurrent paraneoplastic syndromes such as myasthenia gravis and hypercalcemia have been reported; however, their role as prognostic factors is not well determined. Surgical excision is the treatment of choice; adjuvant radiotherapy and/or chemotherapy may prolong survival in cases of incomplete excision or when a thymic carcinoma is diagnosed. Local recurrence and metastasis are infrequently reported; therefore, a long survival time is expected if the tumor is completely excised or if adjuvant therapy is undertaken. This article reports the authors’ experience with 28 dogs affected by 18 thymomas and 10 thymic carcinomas. The median overall survival in this series was 1173 days, and the median disease‐free interval was 903 days. Dogs with thymic carcinoma had significantly shorter disease‐free intervals and shorter, although not statistically significant, survival times. Dogs with Masaoka Stage III tumors had worse outcomes
La radioterapia nel trattamento delle neoplasie maligne del cane e del gatto. PARTE II: APPLICAZIONI CLINICHE ED ESPERIENZA DI 4 ANNI
No full text
Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology
No full textThe field of oncology research has undergone major changes in recent years. Progress in molecular and cellular biology has led to a greater understanding of the cellular pathways and mechanisms of cell proliferation and tissue invasion associated with cancer. New classes of cancer therapies are becoming available or are in development but these new agents require a paradigm shift in the design of oncology clinical trials. This review provides an overview of clinical trial designs for the development of tumour vaccines and targeted therapeutic agents. In addition, some of the successes, limitations and challenges of these trials are discussed, with a special emphasis on the difficulties and particularities that are encountered in veterinary medicine compared to similar work in human patients. (C) 2015 Elsevier Ltd. All rights reserved
Vaccine-associated-like fibrosarcoma at the site of a deep nonadsorbable suture in a cat
No full text
- …
